Myelofibrosis Mortality Trends in the JAK Inhibitor Era: An Age-Stratified Analysis of US Adults Aged 50 and Older, 2018–2024 (SOHO 2026) - Sep 1, 2026 - Abstract #CT-1717; Location: LEVEL 3, HALL B3; "While JAK inhibitors, particularly ruxolitinib (FDA-approved in 2011), have transformed its management, national population-level mortality trends in the contemporary treatment era remain incompletely characterized... Despite JAK inhibitor availability, myelofibrosis-related mortality among US adults aged 50 and older rose gradually from 2018 to 2024, suggesting that therapeutic advances have yet to yield measurable population-level reductions. Disparities by sex, age, and geography, particularly the burden among adults aged 85 and older and Midwest residents, highlight the need for broader access to targeted therapies and age-appropriate treatment strategies. CDC: Centers for Disease Control and Prevention; CI: confidence interval; CMR: complete metabolic response; FDA: US Food and Drug Administration; ICD-10: International Classification of Diseases, 10th Edition; JAK: Janus kinase; OR: odds ratio; STROBE: Strengthening the Reporting of OBservational studies..."
Clinical • Myelofibrosis • Myeloproliferative Neoplasm • Oncology
|
|
Fareed Baksh MBBS 1; Fizza Sajjad MBBS 2; Areesha Nawaz MBBS 3; Sophia Ahmed MBBS 4; Hem Prajapati MBBS 5; Rana Muhammad Ahzam MBBS 1
|